The United Kingdom EVAR Trial Investigators

The United Kingdom EVAR Trial Investigators*

Maartje C.J. Slagman1, Steef J. Sinkeler1, Marc H. Hemmelder2, Femke Waanders1, Liffert Vogt1,
Hanneke C. Kluin-Nelemans3, Gerjan Navis1 and Gozewijn D. Laverman1

Michael C Reade1,2, Lisa Weissfeld3, Derek C Angus2, John A Kellum2, Eric B Milbrandt2*

Toshihiro Fukui, MD, PhD,a Minoru Tabata, MD, MPH,a Susumu Manabe, MD, PhD,a
Tomoki Shimokawa, MD, PhD,a Jun Shimizu, MD, PhD,b Satoshi Morita, MD, PhD,c and
Shuichiro Takanashi, MDa

D P de Arenaza, J Pepper, B Lees, et al.

Narayan Prasad, DM,* Amit Gupta, DNB,* Archana Sinha, MSc,†
Raj Kumar Sharma, DNB,* Anita Saxena, PhD,* Anupama Kaul, DM,*
Dharmender Bhaduria, MD,* and Anurag Gupta, MD*

Lesley A. Stevens, MD, MS,1 Suying Li, PhD,2 Changchun Wang, MS,2 Cindy Huang, MD, PhD,1
Bryan N. Becker, MD, MPH,3 Andrew S. Bomback, MD, MPH,4 Wendy Weinstock Brown, MD, MPH,5
Nilka Ríos Burrows, MPH,6 Claudine T. Jurkovitz, MD,7 Samy I. McFarlane, MD, MPH,8
Keith C. Norris, MD,9 Michael Shlipak, MD,10 Adam T. Whaley-Connell, DO, MSPH,11
Shu-Cheng Chen, MS,2 George L. Bakris, MD,12 and Peter A. McCullough, MD, MPH13

Marc W. Deyell, MD, MSc,a,b William A. Ghali, MD, MPH,b David B. Ross, MD,c Jianguo Zhang, MSc,b and
Brenda R. Hemmelgarn, MD, PhDb for the Alberta Provincial Project for Outcome Assessment in
Coronary Heart Disease (APPROACH) Investigators Vancouver, Calgary, and Edmonton, Canada

MARGARET R. THOMSON, PharmD, BCPS,1 JEAN M. NAPPI, PharmD, BCPS,2,5 STEVEN P. DUNN, PharmD, BCPS,3
IAN B. HOLLIS, PharmD, BCPS,4 JO E. RODGERS, PharmD, BCPS,4 AND ADRIAN B. VAN BAKEL, MD, PhD5